KEY TAKEAWAYS
- The study aimed to investigate how DP traits relate to LAEs in long-term HLSs.
- Researchers noticed that DP in HLSs is linked to late AEs; further investigation is ongoing.
There are limited studies on personality traits among long-term Hodgkin lymphoma survivors (HLSs) who were treated using contemporary stage- and risk-adapted approaches. The Distressed Personality (DP) Scale evaluates negative affectivity and social inhibition.
Alv A Dahl and the team aimed to explore the differences in self-reported late adverse effects (LAEs) between HLSs with and without DP, as well as other explanatory factors.
They performed an inclusive analysis comparing self-reported LAEs between long-term HLSs with and without DP traits. Using the DP Scale, which measures negative affectivity and social inhibition, the study assessed how these traits impacted LAEs.
The analysis also considered other explanatory variables to provide a comprehensive understanding of the relationship between DP and LAEs among patients treated with contemporary stage- and risk-adapted approaches.
The mean age at the survey was 45.9 years (standard deviation [SD] 4.6), with a mean follow-up time of 16.7 years (SD 3.0), and 48% were females. About 82 HLSs had DP, representing 28% (95% CI 23% – 33%). All LAEs except obesity were significantly more common or had higher mean scores in HLSs with DP. In multivariable analyses, the presence of DP was significantly associated with all LAEs except obesity.
The study concluded that DP is prevalent among HLSs and is associated with most self-reported LAEs examined. Incorporating personality trait assessments into survivorship care plans for these patients should be considered. Prospective studies evaluating the impact of pretreatment DP on LAEs are warranted.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/39099321/
Dahl AA, Smeland KB, Eikeland S, et al. (2024). “Distressed personality is associated with late adverse effects in long-term survivors of Hodgkin lymphoma.” Acta Oncol. 2024 Aug 4;63:600-606. doi: 10.2340/1651-226X.2024.40312. PMID: 39099321.
